Last reviewed · How we verify
89Zr-DFO-girentuximab
Targeting CD22
Targeting CD22 Used for Relapsed or refractory CD22-positive B-cell non-Hodgkin lymphoma.
At a glance
| Generic name | 89Zr-DFO-girentuximab |
|---|---|
| Also known as | TLX250-CDx |
| Sponsor | NYU Langone Health |
| Drug class | Monoclonal antibody-drug conjugate |
| Target | CD22 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
89Zr-DFO-girentuximab is a radioligand that targets CD22, a transmembrane sialic acid-binding immunoglobulin-type lectin, which is expressed on the surface of B cells.
Approved indications
- Relapsed or refractory CD22-positive B-cell non-Hodgkin lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 89Zr-DFO-girentuximab CI brief — competitive landscape report
- 89Zr-DFO-girentuximab updates RSS · CI watch RSS
- NYU Langone Health portfolio CI